Advertisement

Induction and Maintenance Agents

  • Adam CochraneEmail author
Living reference work entry
Part of the Organ and Tissue Transplantation book series (OTT)

Abstract

Immunosuppression has increased the success of human heart transplant. There are specific patient groups that benefit from the use of induction therapy though the use of induction therapy has not shown universal benefit for all patients. Currently heart transplant centers employ dual or triple immunosuppression regimens with a calcineurin inhibitor as the base of the regimen and consideration given to antiproliferative agents or PSI/mTOR as the additional agent, with or without corticosteroids. The tolerability of agents can limit their use despite the therapeutic benefit, in addition to immunosuppression, toward renal sparing effects, viral sparing effects, or vasculopathy benefits. The choice of agents make individualization of immunosuppression possible based on a specific patient’s needs.

Keywords

Maintenance immunosuppression Heart transplant induction PSI/mTOR antiviral properties PSI/mTOR CAV C2 monitoring Calcineurin inhibitors Antiproliferative agents 

References

  1. Alberu J, Pascoe MD, Campistol JM et al (2011) Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 92:303–301CrossRefGoogle Scholar
  2. Aliabadi A, Grommer M, Cochrane A et al (2013) Induction therapy in heart transplantation: where are we now? Transpl Int 26:684–695CrossRefGoogle Scholar
  3. Baran DA, Zucker MJ, Arroyo LH et al (2011) A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation, the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Heart Fail 4:129–137CrossRefGoogle Scholar
  4. Barnard JB, Thekkudan J, Richardson S et al (2006) Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation. J Heart Lung Transplant 25(5):564–568CrossRefGoogle Scholar
  5. Bouvier G, Cellerin L, Henry B et al (2009) Everolimus associated interstitial pneumonitis: 3 case reports. Respir Med CME 2(4):181–184CrossRefGoogle Scholar
  6. Brennan DC, Aguada JM, Potena L et al (2013) Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol 23:97–125CrossRefGoogle Scholar
  7. Campbell SB, Walker R, Tai SS et al (2012) Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 12:1146–1156CrossRefGoogle Scholar
  8. Cantarovich M, Besner HG, Barkun JS et al (1998) Two-hour cyclosporine level determination is the appropriate tool to monitor neoral therapy. Clin Transpl 12(3):243–249Google Scholar
  9. Cantarovich M, Giannetti N, Barkun J, Cecere R (2004) Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 75(5):779–781CrossRefGoogle Scholar
  10. Carrier M, Leblanc MH, Perrault LP et al (2007) Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 26:258–263CrossRefGoogle Scholar
  11. Delgado DH, Miriuka MD, Cusimano C et al (2005) Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant 24:166–169CrossRefGoogle Scholar
  12. Euvrard S, Boissonnat P, Roussoulieres A et al (2010) Effect of everolimus on skin cancers in calcineurin inhibitor-treated heart transplant recipients. Transpl Int 23:855–857CrossRefGoogle Scholar
  13. Euvrard S, Morelon E, Rostaing L, et al. (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329–339CrossRefGoogle Scholar
  14. Flaman F, Zieroth S, Rao V, Ross H, Delgado DH (2006) Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant 25:1358–1362CrossRefGoogle Scholar
  15. Grimm M, Rinaldi M, Yonan NA et al (2006) Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant patients – a large European trial. Am J Transplant 6:1387–1397CrossRefGoogle Scholar
  16. Guba M, Graeb C, Jauch KW et al (2004) Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77(12):1777–1782CrossRefGoogle Scholar
  17. Hermann M, Enseleit F, Fisler AE et al (2011) Cyclosporine C0- versus C2-monitoring over three years in maintenance heart transplantation. Swiss Med Wkly 141:w13149PubMedGoogle Scholar
  18. Hertig A, Zuckermann AO (2015) Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: an update. Transpl Immunol 32(3):179–187CrossRefGoogle Scholar
  19. Jeong H, Kaplan B (2007) Therapeutic monitoring of mycophenolate mofetil. CJASN 2(1):184–191CrossRefGoogle Scholar
  20. Kaczmarek I, Ertl B, Schmauss D et al (2006) Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 25(5):550–556CrossRefGoogle Scholar
  21. Kittleson M, Patel J, Rafiei M et al (2013) Failed prednisone taper off after heart transplant: is there a price to be paid? J Heart Lung Transplant 32(4):S200CrossRefGoogle Scholar
  22. Kobashigawa J, Miller L, Renlund D et al (1998) A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66(4):507–515CrossRefGoogle Scholar
  23. Kobashigawa J, Mehra M, West L et al (2009) Report from a consensus conference of the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 28(3):213–225CrossRefGoogle Scholar
  24. Levy G, Thervet E, Lake J et al (2002) Patient management by neoral C2 monitoring: an international consensus statement. Transplantation 73(9):S12–S18CrossRefGoogle Scholar
  25. Marks WH, Ilsley JN, Dharnidkarka VR (2011) Posttransplant lymphoproliferative disorder in kidney and hear transplant patients receiving thymoglobulin: a systematic review. Transplant Proc 43(5):1395–1404CrossRefGoogle Scholar
  26. Masetti M, Potena L, Nardozza M et al (2013) Differential effects of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice. Am J Transplant 13:1217–1226CrossRefGoogle Scholar
  27. Mattei M, Redonnet M, Gandjbakchc I et al (2007) Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti0thymocyte globulin as induction therapy. J Heart Lung Transplant 26:693–699CrossRefGoogle Scholar
  28. Mehra MR, Zucker MJ, Wagoner L et al (2005) A multicenter prospective randomized double blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 24:1297–1304CrossRefGoogle Scholar
  29. Molas-Ferrer G, Soy-Muner D, Anglada-Martinez H et al (2013) Interstitial pneumonitis as an adverse reaction to mTOR. Nefrologia 33(3):297–300PubMedGoogle Scholar
  30. Rosenberg PB, Vriesendorp AE, Drazner MH et al (2005) Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 24:1327–1331CrossRefGoogle Scholar
  31. Salgo R, Grossman J, Schofer H et al (2010) Switch to sirolimus based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 10:1395–1393CrossRefGoogle Scholar
  32. Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60(3):225–232CrossRefGoogle Scholar
  33. Taylor DO, Barr ML, Radovancevic B et al (1999) A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 18:336–345CrossRefGoogle Scholar
  34. Teuteberg JJ, Shullo MA, Zomak R et al (2009) Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 10:382–388CrossRefGoogle Scholar
  35. van Gelder T, Klupp J, Barten MJ et al (2001) Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23(2):19–128Google Scholar
  36. Van Gelder T, Meur YL, Shaw L et al (2006) Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28(2):145–154CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Inova Fairfax HospitalFalls ChurchUSA

Personalised recommendations